Cargando…
Micro RNA 100 sensitizes luminal A breast cancer cells to paclitaxel treatment in part by targeting mTOR
Luminal A breast cancer usually responds to hormonal therapies but does not benefit from chemotherapies, including microtubule-targeted paclitaxel. MicroRNAs could play a role in mediating this differential response. In this study, we examined the role of micro RNA 100 (miR-100) in the sensitivity o...
Autores principales: | Zhang, Baotong, Zhao, Ranran, He, Yuan, Fu, Xing, Fu, Liya, Zhu, Zhengmao, Fu, Li, Dong, Jin-Tang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4868715/ https://www.ncbi.nlm.nih.gov/pubmed/26744318 http://dx.doi.org/10.18632/oncotarget.6790 |
Ejemplares similares
-
ROS, Klotho and mTOR in cardiorenal aging
por: Daneshgar, Nastaran, et al.
Publicado: (2020) -
The mTOR signaling pathway in cardiac aging
por: Dai, Dao-Fu, et al.
Publicado: (2023) -
Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies
por: Alhalabi, Omar, et al.
Publicado: (2023) -
Depletion of Luminal Pyridine Nucleotides in the Endoplasmic Reticulum Activates Autophagy with the Involvement of mTOR Pathway
por: Kapuy, Orsolya, et al.
Publicado: (2013) -
CXCR4 knockdown enhances sensitivity of paclitaxel via the PI3K/Akt/mTOR pathway in ovarian carcinoma
por: Zi, Dan, et al.
Publicado: (2022)